Non-small cell lung cancer: New hope for a chronic illness

Oncology Nursing Forum

Volumn 34, Issue 5, 2007, Pages 963-970

  Tyson, Leslie B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MORTALITY; PATHOLOGY; PROGNOSIS; REVIEW; SEX DIFFERENCE; SMOKING; SURVIVAL RATE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PROGNOSIS; SEX FACTORS; SMOKING; SURVIVAL RATE;

EID: 35549004446     PISSN: 0190535X     EISSN: 15380688     Source Type: Journal    
DOI: 10.1188/07.ONF.963-970     Document Type: Review

References (74)

1. Ahrendt, S.A., Decker, P.A., Alawi, E.A., Zhu Yr, Y.R., Sanchez-Cespedes, M., Yang, S.C., et al. (2001). Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer, 92, 1525-1530.
2. Alberg, A.J., Brock, M.V., & Samet, J.M. (2005). Epidemiology of lung cancer: Looking to the future. Journal of Clinical Oncology, 23, 3175-3185.
3. Alberts, W.M. (2003). Lung cancer guidelines: Introduction. Chest, 123, 1-2.
4. Alexiou, C., Onyeaka, C.V., Beggs, D., Akar, R., Beggs, L., Salama, F.D., et al. (2002). Do women live longer following lung resection for carcinoma? European Journal of Cardio-Thoracic Surgery, 21, 319-325.
5. Arriagada, R., Bergman, B., Dunant, A., LeChevalier, T., Pignon, J.P., & Vansteenkiste, J. (2004). Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. New England Journal of Medicine, 350, 351-360.
6. Barsky, S.H., Cameron, R., Osann, K.E., Tomita, D., & Holmes, E.C. (1994). Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features. Cancer, 73, 1163-1170.
7. Baselga, J., & Arteaga, C.L. (2005). Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. Journal of Clinical Oncology, 23, 2445-2495.
8. Centers for Disease Control and Prevention. (2005a). Cigarette smoking among adults - United States, 2004. Morbidity and Mortality Weekly Report, 54, 1121-1124.
9. Centers for Disease Control and Prevention. (2005b). Tobacco use, access, and exposure to tobacco in media among middle and high school students - United States, 2004. Morbidity and Mortality Weekly Report, 54, 297-301.
10. Cheng, Y.W., Hseih, L.L., Lin, P.P., Chen, C.P., Chen, C.Y., Lim, T.S., et al. (2001). Gender differences in DNA adduct levels among nonsmoking lung cancer patients. Environmental and Molecular Mutagenesis, 37, 304-310.
11. Douillard, J.Y., Rosell, R., Delena, M., Carpagnano, F., Ramlau, R., Gonzales-Larriba, J.L., et al. (2006). Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomized controlled trial. Lancet Oncology, 7, 719-727.
12. Eberhard, D.A., Johnson, B.E., Amler, L.C., Goddard, A.D., Heldens, S.L., Herbst, R.S., et al. (2005). Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. Journal of Clinical Oncology, 23, 5900-5909.
13. Fasco, M.J., Hurteau, G.J., & Spivack, S.D. (2002). Gender-dependent expression of alpha and beta estrogen receptors in human nontumor and tumor lung tissue. Molecular and Cellular Endocrinology, 25, 125-140.
14. Feld, R., Rubinstein, L.V., & Weisenberger, T.H. (1984). Sites of recurrence in resected stage I non-small cell lung cancer: A guide for future studies. Journal of Clinical Oncology, 2, 1352-1358.
15. Ferguson, M.K., Skosey, C., Hoffman, P.C., & Golomb, H.M. (1990). Sex-associated differences in presentation and survival in patients with lung cancer. Journal of Clinical Oncology, 8, 1402-1407.
16. Fontanini, G., Lucchi, M., Vignati, S., Mussi, A., Ciardiello, F., DeLaurentis, M., et al. (1997). Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: A prospective study. Journal of the National Cancer Institute, 89, 881-886.
17. Fossella, F.V., DeVore, R., Kerr, R.N., Crawford, J., Natale, R.R., Dunphy, F., et al. (2000). Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. Journal of Clinical Oncology, 18, 2354-2362.
18. Fu, J.B., Ying Kau, T., Severson, R.K., & Kalem Kerian, G.P. (2005). Lung cancer in women: Analysis of the national Surveillance, Epidemiology, and End Results Database. Chest, 127, 768-777.
19. Grilli, R., Oxman, A.D., & Julian, J.A. ( 1993). Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough? Journal of Clinical Oncology, 11, 1866-1872.
20. Hanna, N., Shepherd, F.A., Fossella, F.V., Pereira, J.R., DeMarinis, F., von Pawel, J., et al. (2004). Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. Journal of Clinical Oncology, 22, 1589-1597.
21. Harpole, D.H., Herndon, J.W., Young, W.G., Wolfe, W.G., & Sabiston, D.C. (1995). Stage I non-small cell lung cancer: A multivariate analysis of treatment methods and patterns of recurrence. Cancer, 76, 787-796.
22. Herbst, R.S., Giaccone, G., Schiller, J.H., Natale, R.B., Miller, V., Manegold, C., et al. (2004). Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. Journal of Clinical Oncology, 22, 785-794.
23. Herbst, R.S., Onn, A., & Sandler, A. (2005). Angiogenesis and lung cancer: Prognostic and therapeutic implications. Journal of Clinical Oncology, 23, 3243-3256.
24. Herbst, R.S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B.E., Sandler, A., et al. (2005). TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. Journal of Clinical Oncology, 23, 5856-5858.
25. Immerman, S.C., Vanecko, R.M., Fry, W.A., Head, L.R., & Shields, T.W. (1981). Site of recurrence in patients with stages I and II carcinoma of the lung resected for cure. Annals of Thoracic Surgery, 32, 23-27.
26. Ingle, R.J. (2000). Lung cancers. In C.H. Yarbro, M.H. Frogge, M. Goodman, & S.L. Groenwald (Eds.), Cancer nursing: Principles and practice (5th ed., pp. 1298-1328.) Sudbury, MA: Jones and Bartlett.
27. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M.J. (2007). Cancer statistics 2007. CA: A Cancer Journal for Clinicians, 57, 43-66.
28. Kaiser, U., Hofmann, J., Schilli, M., Wegmann, B., Klotz, U., Wedel, S., et al. (1996). Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. International Journal of Cancer, 67, 357-364.
29. King, M.W. (2006). Mechanisms of signal transduction. Indiana State University of Medicine. Retrieved April 9, 2007, from http://web.indstate.edu/ thcme/mwking/signal-transduction.html
30. Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, 350, 2129-2139.
31. Marino, P., Pampallona, S., Preatoni, A., Cantoni, A., & Invernizzi, F. (1994). Chemotherapy vs. supportive care in advanced non-small cell lung cancer. Results of a meta-analysis of the literature. Chest, 106, 861-865.
32. Martin, A. (2007, January 31). Stigma aside. Wall Street finds a lot to like about tobacco. The New York Times, A1.
33. Marx, J. (2003). Angiogenesis: A boost for tumor starvation. Science, 301, 452-454.
34. Miller, V.A., Hirsch, F.R., & Johnson, D.H. (2005). Systemic therapy of advanced bronchioloalveolar cell carcinoma: Challenges and opportunities. Journal of Clinical Oncology, 23, 3288-3293.
35. Miller, V.A., Kris, M.G., Shah, N., Patel, J., Azzoli, C., Gomez, J., et al. (2004). Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small cell lung cancer. Journal of Clinical Oncology, 22, 1103-1109.
36. Mountain, C.F. (1997). Revisions in the international system for staging lung cancer. Chest, 111, 1710-1717.
37. Mountain, C.F. (2000). The international system for staging lung cancer. Seminars in Surgical Oncology, 18, 106-115.
38. National Comprehensive Cancer Network. (2007). NCCN clinical practice guidelines in oncology. Non-small-cell lung cancer [v.1.2007]. Retrieved August 11, 2007, from http://www.nccn.org/professionals/physician_gls/PDF/nscl. pdf
39. Non-Small Cell Lung Cancer Collaborative Group. (1995). Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ, 311, 899-909.
40. O'Connell, J., Kris, M.G., Gralla, R.J., Groshen, S., Trust, A., Fiore, J.J., et al. (1986). Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. Journal of Clinical Oncology, 4, 1604-1614.
41. Olaussen, K.A., Dunant, A., Fouret, P., Brambilla, E., Andre, F., Haddad, V., et al. (2006). DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. New England Journal of Medicine, 355, 983-991.
42. Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., et al. (2004). EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science, 304, 497-500.
43. Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sakaria, I., et al. (2004). EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proceedings of the National Academy of Sciences of the United States of America, 101, 13306-13311.
44. Pao, W., & Miller, V.A. (2005). Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions. Journal of Clinical Oncology, 23, 2556-2568.
45. Pao, W., Wang, T.Y., Riely, G.J., Miller, V.A., Pan, Q., Ladnayi, M., et al. (2005). KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib and erlotinib. PLoS Medicine, 2, e13.
46. Patel, J.D. (2005). Lung cancer in women. Journal of Clinical Oncology, 23, 3212-3218.
47. Patel, J.D., Bach, P.B., & Kris, M.G. (2004). Lung cancer in women: A contemporary epidemic. JAMA, 291, 1763-1768.
48. Pham, D., Kris, M.G., Riely, G.J., Inderpal, S.S., McDonough, T., Chuai, S., et al. (2006). Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. Journal of Clinical Oncology, 24, 1700-1704.
49. Pignon, J.P., Tribodet, H., Scagliotti, G.V., Douillard, J.Y. Shepherd, F.A., Stephens, R.J., et al. (2006). Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients. Journal of Clinical Oncology, 24, 7008.
50. Pisters, K.M. (2005). Adjuvant chemotherapy for non-small-cell lung cancer: The smoke clears. New England Journal of Medicine, 352, 2640-2642.
51. Pisters, K.M., & LeChevalier, T. (2005). Adjuvant chemotherapy in completely resected non-small cell lung cancer. Journal of Clinical Oncology, 23, 3270-3278.
52. Potti, A., Mukherjee, S., Petersen, R., Dressman, H.K., Bild, A., Koontz, J., et al. (2006). A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. New England Journal of Medicine, 355, 570-580.
53. Radzikowska, E., Glaz, P., & Roszowski, K. (2002). Lung cancer in women: Age, smoking, histology, performance status, stage, initial treatment and survival - Population-based study of 20,561 cases. Annals of Oncology, 13, 1087-1093.
54. Reed, E. (2006). ERCC1 measurements in clinical oncology. New England Journal of Medicine, 355, 1054-1055.
55. Rosell, R., Cecere, F., Santarpia, M., Reguart, N., & Taron, M. (2006). Predicting the outcome of chemotherapy for lung cancer. Current Opinion in Pharmacology, 6, 323-331.
56. Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., & Dowlati, A., (2006). Paclitaxel-carboplatin alone or with bevacizumab in non-small cell lung cancer. New England Journal of Medicine, 355, 2542-2550.
57. Schiller, J.H., Harrington, D., Belani, C.P., Langer, C., Sandler, A., Krook, J., et al. (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New England Journal of Medicine, 346, 92-98.
58. Schrump, D.S., Altorki, N.K., Henschke, C.L., Carter, D., Turrisi, A.T., & Guiterrez, M.E. (2005). Non-small cell lung cancer. In V.T. DeVita, S. Hellman, & S.A. Rosenberg (Eds.), Cancer: Principles and practice of oncology (7th ed., pp. 189-246). Philadelphia: Lippincott Williams and Wilkins.
59. Shepherd, F.A. (2005). A targeted approach to reducing lung cancer mortality. Journal of Clinical Oncology, 23, 3173-3174.
60. Shepherd, F.A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O'Rourke, M., et al. (2000). Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Journal of Clinical Oncology, 18, 2108-2109.
61. Shepherd, F.A., Pereira, J.R., Ciuleanu, T., Tan, E.H., Hirsh, V., Thongprasert, S., et al. (2005). Erlotinib in previously treated non-small-cell lung cancer. New England Journal of Medicine, 353, 123-132.
62. Socinski, M.A., Morris, D.E., Masters, G.A., & Lilenbaum, R. (2003). Chemotherapeutic management of stage IV non-small cell lung cancer. Chest, 123(Suppl. 1), 226S-243S.
63. Souquet, P.J., Chauvin, F., Boissel, J.P., Cellerino, R., Cormier, Y., Ganz, P.A., et al. (1993). Polychemotherapy in advanced non small cell lung cancer: A meta-analysis. Lancet, 342, 19-21.
64. Spiro, S.G., Rudd, R.M., Shouhami, R.L., Brown, J., Fairlamb, D.J., Gower, N.H., et al. (2004). Chemotherapy versus supportive care in advanced non-small cell lung cancer: Improved survival without detriment to quality of life. Thorax, 59, 828-836.
65. Strauss, G.M., Herndon, J.E., Maddaus, M.A., Johnstone, D.W., Johnson, E.A., Watson, D.M., et al. (2004). Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small-cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) protocol 9633. Journal of Clinical Oncology, 22(14S), 7019.
66. Strauss, G.M., Herndon, J.E., Maddaus, M.A., Johnstone, D.W., Johnson, E.A., Watson, D.M., et al. (2006). Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633 [Abstract]. Journal of Clinical Oncology, 24(18S), 7007.
67. Sun, S., & Schiller, J.H. (2007). Angiogenesis inhibitors in the treatment of lung Cancer. Critical Reviews in Oncology/Hematology, 62, 93-104.
68. Swenberg, J., Richardson, F., Boucheron, J., & Dyroff, M.C. (1985). Relationships between DNA adduct formation and carcinogenesis. Environmental Health Perspectives, 62, 177-183.
69. Taioli, E., & Wynder, E.L. (1994). Endocrine factors and adenocarcinoma of the lung in women. Journal of the National Cancer Institute, 86, 869-870.
70. Thomas, S.K., Fossella, F.V., Liu, D., Schaerer, R., Tsao, A.S., Kies, M.S., et al. (2006). Asian ethnicity as a predictor of response in patients with non-small cell lung cancer treated with gefitinib on an expanded access program. Clinical Lung Cancer, 7, 326-331.
71. Thun, M.J., Lally, C.A., Flannery, J.T., Calle, E.E., Flanders, W.D., & Heath, C.W. (1997). Cigarette smoking and changes in histopathology of lung cancer. Journal of the National Cancer Institute, 89, 1580-1586.
72. Tsao, A.S., Liu, D., Lee, J.J., Spitz, M., & Hong, W.K. (2006). Smoking affects treatment outcome in patients with advanced non-small cell lung cancer. Cancer, 106, 2428-2436.
73. U.S. Department of Health and Human Services. (2001). Women and smoking: A report of the Surgeon General, 2001. Retrieved May 25, 2007, from http://www.cdc.gov/tobacco/data_statistics/sgr/sgr_2001/index.htm
74. Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., et al. (2005). Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. New England Journal of Medicine, 352, 2589-2597.